Lazertinib用于已接受过EGFR TKI治疗且CNS治疗失败的EGFR变异型非小细胞肺癌非随机对照试验

文章预览

SCI 22 August 2024 Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors A Nonrandomized Controlled Trial （IF: JAMA Oncology, 22.5） Hong MH, Choi YJ, Ahn HK, Lim SM, Keam B, Kim DW, Kim TM, Youk J, Kim YJ, Hwang S, Kim S, Kim JW, Kim HR, Kang JH. Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Aug 15:e242640. Corresponding Authors: Hye Ryun Kim, MD, PhD, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea (nobelg@yuhs.ac); Jin Hyoung Kang, MD, PhD, Division of Medical Oncology, Department of Internal Medicine, Seoul St Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, Republic of Korea (oncologykang@naver.c ………………………………